2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
10/25/17Anika Reports Third Quarter 2017 Financial Results
Completed Enrollment in CINGAL Phase III Clinical Trial; Advancement of Regenerative Medicine Pipeline; MONOVISC Revenue Increased 50% Year-over-Year BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 25, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today reported financial results for the third quar... 
Printer Friendly Version
10/25/17Anika Completes Enrollment in Second Pivotal Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis
BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 25, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the completion of enrollment in its second pivotal Phase III trial evaluating CINGAL®, its novel HA-corticosteroid combination viscosupplement1 for the treatment of symptoms associated with osteoarthritis ... 
Printer Friendly Version
10/23/17Anika Announces the Forthcoming Appointment of Thomas M. Finnerty as Chief Human Resources Officer
BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 23, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Thomas M. Finnerty as its Chief Human Resources Officer. Mr. Finnerty brings a 25-year track record of building global human resources teams, and specializes in talent acquisition and de... 
Printer Friendly Version
10/16/17Anika Announces Regulatory Approval for MONOVISC® in Australia for the Treatment of Pain Associated with Osteoarthritis of all Synovial Joints
BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 16, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that regulatory authorities in Australia granted approval to MONOVISC®, Anika’s single injection viscosupplement for the treatment of pain associated with osteoarthritis of all synovial joints, including t... 
Printer Friendly Version
10/11/17Anika to Issue Third-Quarter 2017 Financial Results and Business Highlights on Wednesday, October 25
BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 11, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2017 financial results after the close of the market on Wednesday, October 25, 2017 and to hold a conference call the next day, Thursday, October 26, 2017, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook. The conference call can be accessed by dialing 1... 
Printer Friendly Version
08/28/17Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs
Deep international expertise to drive the Company’s global expansion BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 28, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs. Mr. Chartier brings more than 25 years of op... 
Printer Friendly Version
08/07/17Anika Announces Publication of Data Demonstrating the Efficacy and Safety of HYALOFAST® in Combination with Stem Cells for the Treatment of Cartilage Lesions on the Knee
BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 7, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the publication of data demonstrating that HYALOFAST®, a biodegradable HA-based scaffold, used in combination with autologous adult mesenchymal stem cells (MSCs), regardless of a patients’ age, is a ... 
Printer Friendly Version
07/27/17Anika Announces Appointment of Joseph Darling as President
Track Record of Successful Product Launch and Global Commercial Expansion BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 27, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the appointment of Joseph Darling, an orthopedic and medical device veteran with broad commercial experience, to the role... 
Printer Friendly Version
07/26/17Anika Reports Strong Second Quarter 2017 Financial Results
MONOVISC U.S. End-User Sales Exceeded $100 Million at an Accelerated Pace CINGAL Phase III Clinical Trial Achieved Rapid Advancements BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 26, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today reported financial results for the second quarter ended June 30... 
Printer Friendly Version
07/24/17Anika Announces Regulatory Approval for MONOVISC® in India for the Treatment of Pain Associated with Osteoarthritis of All Synovial Joints
BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 24, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that regulatory authorities in India granted approval to MONOVISC®, its single injection viscosupplement for the treatment of pain associated with osteoarthritis of all human synovial joints. MONOVISC is ... 
Printer Friendly Version
07/17/17Anika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC
Company Expects Total Revenue Growth of 23% to 26% for Q2 2017 BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 17, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that it will receive a $5 million milestone payment under the terms of the Company’s license agreement with its U.S. commercial partner. T... 
Printer Friendly Version
07/12/17Anika to Issue Second-Quarter 2017 Financial Results and Business Highlights on Wednesday, July 26
BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 12, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2017 financial results after the close of the market on Wednesday, July 26, 2017 and to hold a conference call the next day, Thursday, July 27, 2017, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook. The conference call can be accessed by dialing 1-855-... 
Printer Friendly Version
07/06/17Anika to Present at the Singular Research Summer Solstice Conference on July 13, 2017
BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 6, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will make a presentation at the Singular Research Summer Solstice Conference on Thursday, July 13, 2017 at 9:00 am ET. The confere... 
Printer Friendly Version
05/30/17Anika Announces Data Presentation and Symposium on CINGAL at 2017 EFORT Annual Congress
BEDFORD, Mass. & VIENNA--(BUSINESS WIRE)--May 30, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to present Phase III data on CINGAL®, its novel HA-corticosteroid combination viscosupplement, at the 2017 European Federation of National Associations of Orthopedics and Traumatol... 
Printer Friendly Version
05/25/17Anika Announces First Patient Enrolled in Supplemental Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis
BEDFORD, Mass.--(BUSINESS WIRE)--May 25, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the enrollment of the first patient in its supplemental Phase III trial evaluating the efficacy and safety of CINGAL®, its novel HA-corticosteroid combination viscosupplement for the treatment of sym... 
Printer Friendly Version
05/23/17Anika Celebrates 25th Anniversary and Inaugurates Newly Expanded and Consolidated Global Manufacturing Facility in Bedford, Massachusetts
Ribbon-Cutting Ceremony Opens the Doors to State-of-the-Art Facility Built to Supply Global Demand for Anika’s Extensive Commercial Portfolio of More than 20 Products and Technologies BEDFORD, Mass.--(BUSINESS WIRE)--May 23, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, is hosting a celebration today at ... 
Printer Friendly Version
05/22/17Anika Announces Publication of Phase III Data Demonstrating the Efficacy and Safety of CINGAL® for the Treatment of Knee Pain Associated with Osteoarthritis
Positive Data Provides Further Rationale for Strong and Growing Physician Demand for CINGAL following Commercial Launches in Europe and Canada BEDFORD, Mass.--(BUSINESS WIRE)--May 22, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the publication of Phase III data demonstrating the ... 
Printer Friendly Version
04/19/17Anika to Issue First-Quarter 2017 Financial Results and Business Highlights on Wednesday, May 3
BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 19, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2017 financial results after the close of the market on Wednesday, May 3, 2017 and to hold a conference call the next day, Thursday, May 4, 2017, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook. The conference call can be accessed by dialing 1-855-468-0... 
Printer Friendly Version
02/28/17Anika to Present at the 2017 Canaccord Genuity Musculoskeletal Conference on March 14, 2017
BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 28, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that its President and Chief Executive Officer, Charles H. Sherwood, Ph.D., will make a presentation at the 2017 Canaccord Genuity Musculoskeletal Conference on Tuesday, March 14, 2017 at 10:00 am PT. The c... 
Printer Friendly Version
02/15/17Anika Reports Fourth Quarter and Full Year 2016 Financial Results
Worldwide Orthobiologics Revenue Increases 13% Year-over-Year for Fourth Quarter of 2016 Product Revenue Grows 17% for Full Year of 2016 BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 15, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today reported financial results for the fourth quarter and full y... 
Printer Friendly Version
02/01/17Anika to Issue Fourth-Quarter 2016 Financial Results and Business Highlights on Wednesday, February 15
BEDFORD, Mass.--(BUSINESS WIRE)--Feb. 1, 2017-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2016 financial results after the close of the market on Wednesday, February 15, 2017 and to hold a conference call the next day, Thursday, February 16, 2017, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook. The conference call can be accessed by dialing... 
Printer Friendly Version